Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Andrographolide reduced VEGFA expression in hepatoma cancer cells by inactivating HIF-1α: The involvement of JNK and MTA1/HDCA.

Shi L, Zhang G, Zheng Z, Lu B, Ji L.

Chem Biol Interact. 2017 Aug 1;273:228-236. doi: 10.1016/j.cbi.2017.06.024. Epub 2017 Jun 23.

PMID:
28651835
2.

Caloric restriction delays early phases of carcinogenesis via effects on the tissue microenvironment.

Cadoni E, Marongiu F, Fanti M, Serra M, Laconi E.

Oncotarget. 2017 May 30;8(22):36020-36032. doi: 10.18632/oncotarget.16421.

3.

Connectivity map identifies HDAC inhibition as a treatment option of high-risk hepatoblastoma.

Beck A, Eberherr C, Hagemann M, Cairo S, Häberle B, Vokuhl C, von Schweinitz D, Kappler R.

Cancer Biol Ther. 2016 Nov;17(11):1168-1176. Epub 2016 Sep 16.

4.

NFκB1 is a suppressor of neutrophil-driven hepatocellular carcinoma.

Wilson CL, Jurk D, Fullard N, Banks P, Page A, Luli S, Elsharkawy AM, Gieling RG, Chakraborty JB, Fox C, Richardson C, Callaghan K, Blair GE, Fox N, Lagnado A, Passos JF, Moore AJ, Smith GR, Tiniakos DG, Mann J, Oakley F, Mann DA.

Nat Commun. 2015 Apr 16;6:6818. doi: 10.1038/ncomms7818. Erratum in: Nat Commun. 2015;6:8411.

5.

JNJ-26481585, a novel "second-generation" oral histone deacetylase inhibitor, shows broad-spectrum preclinical antitumoral activity.

Arts J, King P, Mariën A, Floren W, Beliën A, Janssen L, Pilatte I, Roux B, Decrane L, Gilissen R, Hickson I, Vreys V, Cox E, Bol K, Talloen W, Goris I, Andries L, Du Jardin M, Janicot M, Page M, van Emelen K, Angibaud P.

Clin Cancer Res. 2009 Nov 15;15(22):6841-51. doi: 10.1158/1078-0432.CCR-09-0547. Epub 2009 Oct 27.

6.

Modulating IGFBP-3 expression by trichostatin A: potential therapeutic role in the treatment of hepatocellular carcinoma.

Gray SG, Kytola S, Lui WO, Larsson C, Ekstrom TJ.

Int J Mol Med. 2000 Jan;5(1):33-41.

PMID:
10601571

Supplemental Content

Loading ...
Support Center